| Index | Value | Change Net / % |
|---|
| Data as of Jul 28, 2017 |
The company's increasing focus on video will be one reason for impending changes
| Company | Last Sale* | Change Net / % | Share Volume |
|---|---|---|---|
|
|
$54 | 5.50 ▼ 9.24% | 50,714,927 |
![]() |
$35.31 | 0.34 ▲ 0.97% | 34,207,256 |
| $143.84 | 0.12 ▼ 0.08% | 33,101,112 | |
![]() |
$29.28 | 0.96 ▼ 3.17% | 30,306,101 |
![]() |
$172.45 | 2.01 ▲ 1.18% | 23,590,406 |
| Company | Last Sale* | Change Net / % | Share Volume |
|---|---|---|---|
| $26.95 | 5.45 ▲ 25.35% | 659,713 | |
| $5.31 | 1.05 ▲ 24.65% | 753,337 | |
![]() |
$4.22 | 0.79 ▲ 23.03% | 4,303,747 |
![]() |
$33.94 | 5.54 ▲ 19.51% | 849,965 |
|
|
$6.96 | 0.87 ▲ 14.29% | 8,046,393 |
| Company | Last Sale* | Change Net / % | Share Volume |
|---|---|---|---|
|
|
$17.25 | 6.40 ▼ 27.06% | 933,370 |
|
|
$139.99 | 49.19 ▼ 26.00% | 791,647 |
|
|
$71.85 | 20.40 ▼ 22.11% | 589,599 |
![]() |
$13.85 | 3.50 ▼ 20.17% | 1,960,729 |
![]() |
$4.45 | 1.10 ▼ 19.82% | 3,293,030 |
| Company | Last Sale* | Change Net / % | Share Volume |
|---|---|---|---|
|
|
$1,020.04 | 25.96 ▼ 2.48% | 7,704,881 |
| $143.84 | 0.12 ▼ 0.08% | 38,009,374 | |
![]() |
$172.45 | 2.01 ▲ 1.18% | 24,550,444 |
|
|
$54 | 5.50 ▼ 9.24% | 53,444,160 |
|
|
$220 | 19 ▲ 9.45% | 12,588,512 |
| Company | Last Sale | Price Change Net / % | Share Volume | Volume % Change |
|---|---|---|---|---|
| $154.05 | 18.40 ▲ 13.56% | 1,303,152 | 763% | |
|
|
$48.55 | 5.775 ▲ 13.50% | 1,182,778 | 596% |
![]() |
$33.94 | 5.54 ▲ 19.51% | 859,710 | 461% |
| $47.54 | 6.92 ▲ 17.04% | 3,973,749 | 448% | |
| $24.91 | .68 ▲ 2.81% | 455,861 | 397% |
| Name | Price Range |
|---|---|
| VENATOR MATERIALS PLC | $20.00 - $22.00 |
| CLEMENTIA PHARMACEUTIC | $13.00 - $15.00 |
Visit Earnings Calendar for the week starting 07/23; 134 reports are scheduled.
| Company | Last Sale* | Change Net / % |
|---|---|---|
| ROP | $232.34 | 0.38 ▲ 0.16% |
|
CLOSEX
|
|
CLOSEX
Please disable your ad blocker (or update your settings to ensure that javascript and cookies are enabled), so that we can continue to provide you with the first-rate market news and data you've come to expect from us.
CLOSEX
|